Andrew C. Hsieh

Dr. Andrew C. Hsieh is a distinguished physician-scientist holding dual appointments at Fred Hutch Cancer Center and University of Washington. At Fred Hutch, he serves as Professor and Associate Director of the Human Biology Division, Professor of the Clinical Research Division, and maintains a professorship in the Division of Hematology and Oncology at the University of Washington School of Medicine. His clinical practice focuses on genitourinary cancers at Fred Hutch Cancer Center at UW Medical Center – Montlake, where he treats patients with prostate and bladder cancers while balancing clinical care with laboratory research.

Dr. Hsieh earned his medical degree from Albert Einstein College of Medicine and completed both residency and fellowship training at University of California, San Francisco. He is board-certified in Medical Oncology and Internal Medicine by the American Board of Internal Medicine. His educational background provided the foundation for his dual career path as both clinician and researcher, allowing him to bridge discoveries from bench to bedside.

Dr. Hsieh's research program centers on understanding how cancer cells hijack protein synthesis mechanisms to drive tumor growth and progression. The Hsieh laboratory investigates the deregulation of protein synthesis control in epithelial cells during the multi-step process of tumor initiation and progression, with particular emphasis on prostate and bladder cancers. His team aims to merge fundamental discoveries in translational control biology with the clinical needs of cancer patients, developing novel therapeutic approaches that selectively target cancer-specific protein synthesis pathways while sparing normal cells. This work has significant implications for overcoming therapy resistance in advanced cancers.

Analysis of Dr. Hsieh's extensive publication record reveals a consistent research trajectory focused on translational control mechanisms in cancer biology. His work spans from basic molecular mechanisms of protein synthesis regulation to clinical applications in cancer treatment, with an increasing emphasis on precision medicine approaches for genitourinary malignancies. Key research themes include understanding therapy resistance mechanisms, identifying novel druggable targets in protein synthesis pathways, and developing biomarker-driven treatment strategies for prostate and bladder cancers. His collaborative approach is evident in numerous multidisciplinary studies involving clinical data analysis, molecular biology techniques, and translational research methodologies.

• $1 million grant for London-Seattle collaboration to develop new therapies for drug-resistant prostate cancer
• Multiple high-impact publications in journals including Nature, Cell, Cancer Cell, and Nature Communications
• Active participation in clinical trials for novel cancer therapeutics
• Recognition as a leading expert in translational control mechanisms in cancer

As a physician-scientist, Dr. Hsieh mentors numerous trainees and collaborates extensively with both basic science and clinical researchers. His laboratory at Fred Hutch employs a multidisciplinary approach that integrates molecular biology, genomics, and clinical research to address fundamental questions about how cancer cells co-opt protein synthesis machinery. The Hsieh lab has developed innovative methodologies including CRISPR screening approaches to understand RNA-binding proteins in cancer, and has pioneered research on how transcriptional-translational conflicts serve as barriers to cellular transformation. Dr. Hsieh's commitment to translating basic discoveries into clinical applications is evident in his active involvement in clinical trials and his focus on developing novel therapeutic strategies for patients with advanced genitourinary cancers.